VNDA Earnings — Vanda Pharmaceuticals Inc. Post-ER Performance | BigEarnings
VNDA — Vanda Pharmaceuticals Inc.
XNAS · Healthcare · Biotechnology
Price$6.45
Market Cap$387.9M
P/E—
52W Range$4.14 – $9.94
Next Earnings2026-07-30
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
